The problem of long-term pain control in chronic rheumatic diseases
https://doi.org/10.14412/1996-7012-2022-2-87-91
Abstract
Pain is one of the main symptoms and the most distressing manifestation of rheumatic diseases (RD). Currently, non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for the symptomatic treatment of RD in real clinical practice, but the effectiveness and tolerability of their longterm use remain insufficiently studied. Many patients with RD require long-term use of NSAIDs. In this case, the presence of comorbid pathology and risk factors for the development of drug complications should be taken into consideration, so the choice of NSAIDs should be based primarily on considerations of patient safety. Aceclofenac (Aertal®) has a pronounced analgesic potential and a good safety profile, which allows us to recommend it for long-term use.
About the Authors
E. Yu. Polishchuk
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Elena Yurievna Polishchuk
34A, Kashirskoe shosse, Moscow 115522, Russia
A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522, Russia
References
1. Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2020. 448 p.
2. Steffen А, Holstiege J, Klimke K, et al. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data. Rheumatol Int. 2018 Nov;38(11):2111-20. doi: 10.1007/s00296-018-4161-7. Epub 2018 Oct 10.
3. Black RJ, Richards B, Lester S, et al. Factors associated with commencing and ceasing opioid therapy in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019 Dec;49(3):351-7. doi: 10.1016/j.semarthrit.2019.06.003
4. Kimsey L, Weissman JS, Patel A, et al. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries. Semin Arthritis Rheum. 2019 Apr;48(5):821-7. doi: 10.1016/j.semarthrit.2018.07.003.
5. Crossfield SSR, Buch MH, Baxter P, Kingsbury SR, Pujades-Rodriguez M, Conaghan PG. Changes in the pharmacological management of rheumatoid arthritis over two decades. Rheumatology (Oxford). 2021 Sep 1; 60(9):4141-51. doi: 10.1093/rheumatology/keaa892.
6. Karateev AE, Pogozheva EYu, Amirdzhanova VN, et al. Regular use of non-steroidal anti-inflammatory drugs can effectively control pain and global health in patients with moderate activity of rheumatoid arthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(2):57-63. (In Russ.). doi: 10.14412/1996-7012-2021-2-57-63.
7. Lila AM, Alekseeva LI, Taskina EA. Modern approaches to the treatment of osteoarthritis taking into account the updated international recommendations. Russkii meditsinskii zhurnal. 2019;(3):48-52. (In Russ.).
8. Collins JE, Katz JN, Dervan EE, Losina E. Trajectories and risk profiles of pain in persons with radiographic, symptomatic knee osteoarthritis: data from the osteoarthritis initiative. Osteoarthritis Cartilage. 2014 May;22(5):622-30. doi: 10.1016/j.joca.2014.03.009. Epub 2014 Mar 21.
9. Curtis SP, Bockow B, Fisher C, et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord. 2005 Dec 1;6:58. doi: 10.1186/1471-2474-6-58.
10. Dahlberg LE, Holme I, Høye K, Ringertz B. A randomized, multicentre, doubleblind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scand J Rheumatol. Mar-Apr 2009;38(2):133-43. doi: 10.1080/03009740802419065.
11. Pelletier JP, Raynauld JP, Beaulieu AD, et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther. 2016 Nov 3;18(1):256. doi: 10.1186/s13075-016-1149-0.
12. Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. doi: 10.1136/ard.2006.059162. Epub 2006 Dec 1.
13. Langdon CG, Moran DG, Jamieson V, et al. A multicentre study of tenoxicam for the treatment of osteo-arthritis and rheumatoid arthritis in general practice. J Int Med Res. Nov-Dec 1990;18(6):489-96. doi: 10.1177/030006059001800607.
14. Schattenkirchner M. Long-term safety of ketoprofen in an elderly population of arthritic patients. Scand J Rheumatol Suppl. 1991; 91:27-36. doi: 10.3109/03009749109096948.
15. Gaidukova IZ, Rebrov AP, Lapshina SA, et al. The use of nonsteroidal anti-inflammatory drugs and genetically engineered biological drugs for the treatment of axial spondyloarthritis. Recommendations of the Expert Group on the study of spondyloarthritis at the All-Russian Public Organization «Association of Rheumatologists of Russia». Nauchnoprakticheskaya revmatologiya. 2017;55(5):474-84. (In Russ.).
16. Van der Heijde D, Ramiro S, Landew R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun; 76(6):978-91. doi: 10.1136/annrheumdis- 2016-210770. Epub 2017 Jan 13.
17. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019 Oct; 71(10):1285-99. doi: 10.1002/acr.24025.
18. Erdes ShF. Recent advances and prospects of axial spondyloarthritis / ankylosing spondylitis treatment. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(2):94-105. (In Russ.). doi: 10.14412/1996-7012-2021-2-94-105
19. Iolascon G, Gimйnez S, Mogyorуsi D. A Review of Aceclofenac: Analgesic and AntiInflammatory Effects on Musculoskeletal Disorders. J Pain Res. 2021 Nov 30;14:3651-63. doi: 10.2147/JPR.S326101. eCollection 2021.
20. Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: a meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-8. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.
21. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1; 35(12):1127-46. doi: 10.2165/11633470-000000000-00000.
22. Masclee GMC, Straatman H, Arfи A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested casecontrol study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.
23. Karateev AE, Tsurkan AV. Aceclofenac: the experience of Russian research. Sovremennaiya revmatologiya = Modern Rheumatology Journal. 2017;11(4):89-94. (In Russ.). doi:10.14412/1996-7012-2017-4-89-94.
24. Karateev AE, Polishchuk EYu, Filatova ES, et al. Long-term use of nonsteroidal anti-inflammatory drugs for pain control in patients with osteoarthritis: results of the 12-month observational study AELITA (Analgesia: Effective Treatment Using The Therapeutic Algorithm). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(6):84-90. (In Russ.). doi: 10.14412/1996-7012-2021-6-84-90
Review
For citations:
Polishchuk EY, Karateev AE. The problem of long-term pain control in chronic rheumatic diseases. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022;16(2):87-91. (In Russ.) https://doi.org/10.14412/1996-7012-2022-2-87-91
Views:
418
Email this article 